Estimate the prevalence of impaired renal function to residents of Almaty and Almaty region

Purpose. To study the prevalence of renal dysfunction (NFP) as determined by glomerular filtration rate (CKD-EPI, KDIGO, 2024) among the residents of Almaty and Almaty region.
The materials and methods. 1575 adults aged 18 to 69 years, determining RF performed formula CKDEPI, including sex, age of the patient and the concentration of creatinine in the serum, except in the analysis
included age and gender, social characteristics, and risk factors for cardiovascular disease: increased total cholesterol (TC); Low-density lipoprotein (LDL); High density lipoprotein cholesterol, triglycerides; determined by the degree of abdominal adiposity, fasting plasma glucose.
The results.GFR was estimated at 1 553 respondents, which accounted for 97.2 % of cases of observation, mean GFR in the whole study population was 101,9 ± 18,2 ml / min / 1.73 m2, those with high / optimal SCF (76.7 %) and persons with reduced GFR (23.2 %) among respondents with renal dysfunction according to GFR, living in Almaty and the region women were significantly more likely (90%), older persons (37.1% ), residents of the city (72.3%) and respondents who suffer from joint-stock company (75 %) and a high degree of hypertension (25.88 %).
The conclusion. In assessing renal function, defined by GFR determined by the formula CKD-EPI, KDIGO, 2024 among residents of Almaty and Almaty region, decreased renal function was determined in 23.2 % of respondents, while in this group were significantly more frequent faces female, older age group (60-69 years), residents of the city, among the important cardiometabolic risk factors were abdominal obesity, high degree of hypertension.

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, 105(4), 117-314, DOI: 10.1016/j.kint.2023.10.018.

2. Cerasola, G., Nardi, E., Palermo, A. et al. (2011). Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. Journal of Nefrology, 24(1), 1-10.

3. Collins, A. Y., Vassalotti, J. A., Wang, C. et al. (2009). Who should be targeted for CKD screening? Impact of diabetes, hypertension and cardiovascular disease. American Journal of Kidney Disease, 53(3), 71-77.

4. Smirnov, А. V., Dobronravov, V. А., Kayukov, I. G. et al. (2008). Rekomendacii Nauchnoissledovatel'skogo instituta nefrologii Sankt-Peterburgskogo gosudarstvennogo medicinskogo universiteta im. akad. I. P. Pavlova: opredelenie, klassifikaciya, diagnostika i osnovnye napravleniya profilaktiki hronicheskoj bolezni pochek u vzroslyh. Saint Petersburg: Levsha, 51 (In Russian).

5. Sharon, M. M., Geoffrey, A. B., Jorge, B. C. et al. (2009). Kidney Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International, 76(113), 130 p.

6. Russian National Recommendations. Hronicheskaya bolezn' pochek: osnovnye principy skrininga, diagnostiki, profilaktiki i podhody k lecheniyu. Saint Petersburg 2013, 52 p. (In Russian).

7. Coresh, J., Selvin, E., Stevens, L. A. et al. (2008). Prevalence of chronic kidney disease in the United States. JAMA, 298(17), 2038-2047, DOI:10.1001/jama.298.17.2038.

8. Mann, J. F., Schmieder, R. E., McQueen, M. et al. (2008). Renal outcomes with telmisartan, ramipril, both, in people at high vascular resk (the ONTARGET study): a multicentre, randonised, double – blind, controlled trial. Lancet, 372(9638), 547-553.

9. Smirnov, A. V., Dobronravov, V. A., Kayukov, I. G. (2005). Kardio-renal'nyj kontinuum: patogeneticheskie osnovy preventivnoj kardiologii. Nephrology 3, 7-15 (In Russian).

10. Baigent, C., Burbury, K., Wheeler, D. (2000). Premature cardiovascular disease in chronic renal failure. Lancet, 356(8), 147-152.

11. Ruggenenti, P., Schieppati, A., Remuzzi, G. (2001). Progression, remission, regression of chronic renal diseases. Lancet, 357, 1601-1608.

12. USPSTF. Screening f or Chronic Kidney Disease: U.S. (2012). Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 157(8), 567-570.

13. Tomilina, N. A., Bikbov, B. T. (2005). Epidemiologiya hronicheskoj pochechnoj nedostatochnosti i novye podhody k klassifikacii i ocenke tyazhesti hronicheskih progressiruyushchih zabolevanij pochek. Terapevticheskii arkhiv, 6, 28-33 (In Russian).

14. World Health Organization. The WHO STEPwise approach to noncommunicable disease risk factor surveillance (STEPS). Retrived May 16, 2024, from https://www.who.int/teams/noncommunicable-%20countries.